PL8177

Phase 2Small molecule

PPalatin Technologies, Inc

PL8177 is one of 36 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Phase 3

2 2

Mesalazine

Ferring

Phase 3

17 3

CP-690,550

Pfizer

Phase 3

2 4

PTM SEMA

Gilead

Phase 3

1 5

JNJ-42756493

RPC1063

2 7

Etrolizumab

Roche

Phase 3

7 8

Simponi

Johnson & Johnson

Preclinical

15 9

CT-P13 SC (infliximab)

CCelltrion

Phase 3

1 10

Remicade

OOrganon and Co

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

Active, not recruiting·PPalatin Technologies, Inc·Phase 2·NCT05466890·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PL8177. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PL8177 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PL8177. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Palatin Technologies, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPalatin Technologies, Inc

PL8177

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News